ArticleActa pharmaceutica Sinica. B2023
A tactical nanomissile mobilizing antitumor immunity enables neoadjuvant chemo-immunotherapy to minimize postsurgical tumor metastasis and recurrence.
Article in Acta pharmaceutica Sinica. B, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 22 citations in OpenAlex.
- Hierarchical drug-releasing nanocomposite hydrogel for postoperative synergistic chemo-photothermal therapy of uveal melanoma.Materials today. Bio · 2026Article
- Advanced drug delivery platforms targeting cellular senescence: A promising strategy for cancer therapy.Acta pharmaceutica Sinica. B · 2026Review
- Enhanced mRNA vaccine combined with immune checkpoint blockade efficiently suppresses tumor growth and metastasis.Journal of nanobiotechnology · 2026Article
- Neutrophil-based delivery platforms: from natural mechanisms to engineered therapeutics.Theranostics · 2026Review
- Biomaterials in pancreatic surgery: progress and challenges in preoperative, intraoperative and postoperative care.Theranostics · 2026Review
- Limitation-circumventing and strength-capitalizing hydrogel potentiates durable antitumor immunity and robust abscopal effect in radiotherapy.Theranostics · 2026Article
- Precise Catalysis and Immune Activation: New Strategies for Tumor Immunotherapy with Cascade Nanozymes.International journal of nanomedicine · 2026Review
- Multi-responsive nanocomposite hydrogel for synergistic photothermal-chemotherapy to prevent postoperative recurrence and metastasis of uveal melanoma.Materials today. Bio · 2025Article
- Magnetic continuum soft robot-driven precise delivery of prodrug nanoassemblies for gastric cancer chemo-immunotherapy.Asian journal of pharmaceutical sciences · 2025Article
- Biomaterials nanoplatform-based tumor vaccines for immunotherapy.Bioactive materials · 2025Review
- Improvement of the Anticancer Efficacy of PD-1/PD-L1 Blockade: Advances in Molecular Mechanisms and Therapeutic Strategies.MedComm · 2025Review
- Conversion TORS after neoadjuvant immunotherapy for advanced BOT-SCC: a retrospective study.Frontiers in oncology · 2025Article
- Nanotechnology Integrated Innovative Drug Delivery and Therapy for Cancer.Current pharmaceutical biotechnology · 2025Review
- Metabolic Targeting of Oxidative Phosphorylation Enhances Chemosensitivity in Triple-Negative Breast Cancer via a Synergistic Nanomedicine.Theranostics · 2025Article
- GSH-responsive polymeric micelles-based augmented photoimmunotherapy synergized with PD-1 blockade for eliciting robust antitumor immunity against colon tumor.Journal of nanobiotechnology · 2024Article
- Reversing cancer immunoediting phases with a tumor-activated and optically reinforced immunoscaffold.Bioactive materials · 2024Article
- A hierarchically acidity-unlocking nanoSTING stimulant enables cascaded STING activation for potent innate and adaptive antitumor immunity.Theranostics · 2024Article
- Chemotherapy-induced metastasis: molecular mechanisms and clinical therapies.Acta pharmacologica Sinica · 2023Review
- Cancer nanomedicine in preoperative therapeutics: Nanotechnology-enabled neoadjuvant chemotherapy, radiotherapy, immunotherapy, and phototherapy.Bioactive materials · 2023Review
- Nanomaterial-Based Antivascular Therapy in the Multimodal Treatment of Cancer.Pharmaceutics · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neoadjuvant chemotherapy has become an indispensable weapon against high-risk resectable cancers, which benefits from tumor downstaging. However, the utility of chemotherapeutics alone as a neoadjuvant agent is incapable of generating durable therapeutic benefits to prevent postsurgical tumor metastasis and recurrence. Herein, a tactical nanomissile (TALE), equipped with a guidance system (PD-L1 monoclonal antibody), ammunition (mitoxantrone, Mit), and projectile bodies (tertiary amines modified azobenzene derivatives), is designed as a neoadjuvant chemo-immunotherapy setting, which aims at targeting tumor cells, and fast-releasing Mit owing to the intracellular azoreductase, thereby inducing immunogenic tumor cells death, and forming an
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.